Rigel's not having shown efficacy in TNF failures is a large weakness
it certainly puts them out of the tnf failure market, but the larger piece of the pie is MTX failures (i.e supplanting the TNF market). if they can show differentiation of their drug with PFEs they will do well commercially - and they just might despite having failed to show efficacy in TNF failures
i don;t think a head to head with PFE's drug is going to happen any time soon if at all, and it's hard to compare across studies, but the ACR 70 of rigel's drug carries over in phase 3 it will be better than PFE's efficacy on this metric and would make it marketable head to head imo
also they may have efficacy in jak inhibitor failures since they are differentiated in class, which in and of itself could eventually be a sizeable market
Market Data 
Markets 
AI
